Rapport Therapeutics
(NASDAQ) RAPP
Rapport Therapeutics Financials at a Glance
Market Cap
$1.75B
Revenue (TTM)
$0.00
Net Income (TTM)
$111.48M
EPS (TTM)
$-2.87
P/E Ratio
-12.76
Dividend
$0.00
Beta (Volatility)
1.46 (Average)
Dividend
$0.00
Beta (Volatility)
1.46 (Average)
Price
$36.62
Volume
230,307.271
Open
$36.59
Price
$36.62
Volume
230,307.271
Open
$36.59
Previous Close
$36.56
Daily Range
$35.64 - $37.01
52-Week Range
$7.73 - $42.27
Dividend
$0.00
Beta (Volatility)
1.46 (Average)
Price
$36.62
Volume
230,307.271
Open
$36.59
Previous Close
$36.56
Daily Range
$35.64 - $37.01
52-Week Range
$7.73 - $42.27
RAPP News
RAPP: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Rapport Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
84
CEO
Abraham N. Ceesay, MBA
Website
www.rapportrx.comHeadquarters
Boston, DE, US
RAPP Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-28%
Return on Capital
-25%
Return on Assets
-22%
Earnings Yield
-7.84%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.75B
Shares Outstanding
47.79M
Volume
230.31K
Short Interest
0.00%
Avg. Volume
345.20K
Financials (TTM)
Gross Profit
$1.02M
Operating Income
$125.10M
EBITDA
$124.08M
Operating Cash Flow
$87.47M
Capital Expenditure
$616.00K
Free Cash Flow
$88.09M
Cash & ST Invst.
$490.54M
Total Debt
$11.48M
Rapport Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$265.00K
N/A
Gross Margin
0.00%
N/A
Market Cap
$1.75B
N/A
Market Cap/Employee
$25.32M
N/A
Employees
69
N/A
Net Income
$33.76M
-69.0%
EBITDA
$38.24M
-64.4%
Quarterly Fundamentals
Net Cash
$479.06M
+57.7%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$8.73M
+1081.2%
Short Term Debt
$2.75M
+273.8%
Return on Assets
-21.76%
N/A
Return on Invested Capital
-25.36%
N/A
Free Cash Flow
$24.70M
-68.4%
Operating Cash Flow
$24.70M
-71.0%